

7 November 2018

Dear fellow investor,

Chairman's Update

The Global Disruption Fund (**Fund**) performed well again in the September quarter.

The reporting season was on balance a good set of results for the Fund, highlighting the companies we invested in overall are meeting expectations and, in many cases, exceeding them.

The theme of disruptive technology and innovation remains relevant and a significant contributor to markets going forward. This influence is likely to be sustained given the continued and substantial growth in corporate IT spending, which was one of the most notable aspects of our Portfolio Manager, Raymond Tong's, recent trip to the US.

Chinese stocks were comparatively weaker this quarter, due to concerns around the US-China trade war and slowing Chinese growth. Nevertheless, we remain confident in the long-term positioning of the Chinese companies held in the Fund.

The Investment Committee continues to examine global markets for new industries and enterprise disrupting traditional operating models or developing new pathways to customers. We also actively review the Fund's existing holdings and exposures considering emerging trends and changing circumstances.

The progress of research and innovation in medicine is one such area where treatment options are rapidly changing and this quarter the Fund made its first investments in the medical technology (Medtech) sector. The Fund has invested in Illumina, a business at the forefront of genetic sequencing technology and in Merck, an established pharmaceutical company pioneering new cancer treatments using immunotherapy. We remain confident in the Fund's significant shareholdings and the merits of these investments, with pleasing quarterly results and recent market disclosures from these companies.

This quarter we successfully completed a further capital raising, demonstrating strong support for the Funds mandate to invest in companies that will be beneficiaries of advances in technology and disruptive innovation of markets and industries.

Please find attached the September 2018 quarterly update for the Fund.

Yours sincerely,

David Evans